Pathos, an AI-driven drug development company, raised a $237 million Series E at a $3 billion valuation, led by Bristol Myers Squibb. Pathos said it is also expanding from oncology into neurological conditions, citing new datasets from Tempus AI and a partnership with BMS that will initially focus on Alzheimer’s treatments. The financing highlights how major pharma is increasingly funding AI-native discovery engines, with Pathos describing its proprietary Foundry system as running thousands of agents to estimate probability of success for clinical assets. The agents are said to analyze clinical, genomics, specimen and competitive landscapes to guide program selection, population targeting and trial design. From an industry standpoint, the round signals continued appetite for platform-style partnerships where pharma can underwrite discovery risk while retaining optionality on downstream programs. It also adds a new competitor to the crowded AI drug discovery field, where differentiation increasingly depends on data pipelines and validation loops rather than model marketing alone. For biotech professionals watching funding dynamics, the combination of a large Series E and a strategic investor underscores that AI discovery is moving from experimentation to sustained capital commitments.